ICU Medical (NASDAQ:ICUI) Receives Hold Rating from Needham & Company LLC

Needham & Company LLC reiterated their hold rating on shares of ICU Medical (NASDAQ:ICUI - Free Report) in a research report sent to investors on Wednesday,Benzinga reports.

Several other research firms have also recently issued reports on ICUI. Jefferies Financial Group began coverage on shares of ICU Medical in a report on Monday, October 14th. They issued a "hold" rating and a $183.00 target price for the company. StockNews.com lowered shares of ICU Medical from a "buy" rating to a "hold" rating in a research note on Tuesday. KeyCorp lifted their price objective on shares of ICU Medical from $147.00 to $198.00 and gave the stock an "overweight" rating in a research report on Tuesday, October 15th. Finally, Raymond James increased their target price on ICU Medical from $158.00 to $190.00 and gave the company an "outperform" rating in a report on Thursday, September 12th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $173.00.

ICU Medical Price Performance

ICUI stock traded down $0.22 during midday trading on Wednesday, reaching $177.79. The company had a trading volume of 436,886 shares, compared to its average volume of 274,031. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.08 and a current ratio of 2.41. The stock has a 50 day moving average price of $175.85 and a 200 day moving average price of $141.75. ICU Medical has a fifty-two week low of $82.82 and a fifty-two week high of $196.26.

ICU Medical (NASDAQ:ICUI - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The medical instruments supplier reported $1.23 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.35. ICU Medical had a negative net margin of 4.74% and a positive return on equity of 5.04%. The firm had revenue of $580.07 million for the quarter, compared to the consensus estimate of $574.77 million. On average, equities analysts predict that ICU Medical will post 3.81 earnings per share for the current fiscal year.

Insider Activity at ICU Medical

In related news, CEO Vivek Jain sold 12,000 shares of the company's stock in a transaction on Friday, August 16th. The stock was sold at an average price of $156.04, for a total value of $1,872,480.00. Following the completion of the transaction, the chief executive officer now directly owns 104,593 shares in the company, valued at approximately $16,320,691.72. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other ICU Medical news, VP Daniel Woolson sold 2,502 shares of the firm's stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $163.22, for a total transaction of $408,376.44. Following the completion of the transaction, the vice president now owns 13,107 shares in the company, valued at $2,139,324.54. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $156.04, for a total value of $1,872,480.00. Following the sale, the chief executive officer now directly owns 104,593 shares in the company, valued at $16,320,691.72. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 50,502 shares of company stock worth $8,445,976 over the last three months. Company insiders own 6.70% of the company's stock.

Hedge Funds Weigh In On ICU Medical

Several institutional investors have recently added to or reduced their stakes in ICUI. FMR LLC increased its holdings in ICU Medical by 2,676.6% during the 3rd quarter. FMR LLC now owns 104,094 shares of the medical instruments supplier's stock valued at $18,968,000 after purchasing an additional 100,345 shares in the last quarter. Cerity Partners LLC grew its holdings in shares of ICU Medical by 33.2% during the third quarter. Cerity Partners LLC now owns 9,846 shares of the medical instruments supplier's stock worth $1,794,000 after purchasing an additional 2,454 shares during the last quarter. Citigroup Inc. increased its stake in shares of ICU Medical by 100.4% in the third quarter. Citigroup Inc. now owns 28,965 shares of the medical instruments supplier's stock valued at $5,278,000 after buying an additional 14,512 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of ICU Medical by 10.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 301,107 shares of the medical instruments supplier's stock valued at $54,868,000 after buying an additional 27,927 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new position in ICU Medical during the 3rd quarter worth about $815,000. 96.10% of the stock is owned by institutional investors.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.